35.16

0.54% -0.245

Ionis Pharmaceuticals Inc (IONS)

Panoramica Notizia Cronologia dei prezzi Catena di opzioni Financials Forum Previsione

Precedente Chiudi:

$35.40

Aprire:

$35.62

Volume 24 ore:

132.30K

Relative Volume:

0.08

Capitalizzazione di mercato:

$5.17B

Reddito:

$813.46M

Utile/perdita netta:

$-365.74M

Rapporto P/E:

-12.25

EPS:

-2.87

Flusso di cassa netto:

$-375.18M

1 W Prestazione:

-5.43%

1M Prestazione:

-9.72%

6M Prestazione:

-5.78%

1 anno Prestazione:

-28.20%

Intervallo 1D:

$34.83

$35.65

Intervallo di 1 settimana:

$33.33

$37.29

Portata 52W:

$33.33

$54.44

Ionis Pharmaceuticals Inc Stock (IONS) Company Profile

Nome

Ionis Pharmaceuticals Inc

Settore

Healthcare (1195)

Industria

Biotechnology (683)

Telefono

(760) 931-9200

Indirizzo

2855 GAZELLE COURT, CARLSBAD, CA

Dipendente

927

Cinguettio

@ionispharma

Prossima data di guadagno

2024-11-06

Ultimi documenti SEC

IONS's Discussions on Twitter

Confronta IONS con altri titoli

Azioni	Prezzo	Cap. di mercato	Reddito	Reddito netto	Flusso di cassa	EPS
IONS	35.13	5.17B	813.46M	-365.74M	-375.18M	-2.87
VRTX	446.61	115.74B	10.63B	-479.80M	-1.35B	13.33
REGN	741.51	81.65B	13.85B	4.65B	3.32B	35.06
ARGX	592.00	34.86B	1.86B	-40.29M	-1.28B	-4.16
ALNY	250.23	32.09B	2.09B	-332.26M	16.06M	-4.14
BNTX	103.42	24.49B	3.30B	-501.07M	1.03B	11.54

Ionis Pharmaceuticals Inc Stock (IONS) Upgrades & Downgrades

Data	Azione	Analista	Modifica della valutazione
2024-01-02	Aggiornamento	BofA Securities	Neutral → Buy
2023-10-23	Aggiornamento	BofA Securities	Underperform → Neutral
2023-09-29	Iniziato	Raymond James	Strong Buy
2023-07-31	Aggiornamento	Citigroup	Neutral → Buy
2023-06-07	Ripresa	Piper Sandler	Overweight
2023-05-04	Aggiornamento	Citigroup	Sell → Neutral
2023-03-21	Iniziato	Bernstein	Underperform
2022-12-21	Downgrade	Morgan Stanley	Overweight → Equal-Weight
2022-09-09	Ripresa	Morgan Stanley	Overweight
2022-07-18	Ripresa	Oppenheimer	Outperform
2022-03-31	Ripresa	Piper Sandler	Overweight
2022-03-01	Iniziato	Citigroup	Sell
2022-03-01	Iniziato	Guggenheim	Buy
2022-02-01	Downgrade	BofA Securities	Buy → Underperform
2021-12-14	Aggiornamento	William Blair	Mkt Perform → Outperform
2021-05-07	Aggiornamento	UBS	Sell → Neutral
2021-03-01	Aggiornamento	Barclays	Underweight → Equal Weight
2020-12-16	Iniziato	UBS	Sell
2020-12-15	Aggiornamento	Cowen	Market Perform → Outperform
2020-09-14	Ripresa	JP Morgan	Neutral
2020-09-02	Iniziato	The Benchmark Company	Hold
2020-06-01	Ripresa	Oppenheimer	Outperform
2020-05-13	Iniziato	RBC Capital Mkts	Outperform
2020-03-05	Iniziato	Citigroup	Buy
2019-12-13	Iniziato	Oppenheimer	Outperform
2019-11-13	Iniziato	BofA/Merrill	Buy
2019-11-07	Downgrade	Morgan Stanley	Equal-Weight → Underweight
2019-09-10	Aggiornamento	Bernstein	Mkt Perform → Outperform
2018-08-08	Reiterato	Stifel	Hold
2018-08-07	Reiterato	Stifel	Hold
2018-05-08	Downgrade	Evercore ISI	Outperform → In-line
2017-10-06	Ripresa	Goldman	Sell
2017-08-17	Iniziato	Evercore ISI	Outperform
2017-08-09	Reiterato	Stifel	Hold
2017-03-10	Downgrade	Goldman	Neutral → Sell
2016-12-28	Reiterato	BMO Capital Markets	Outperform
2016-12-27	Reiterato	Leerink Partners	Mkt Perform

Mostra tutto

Ionis Pharmaceuticals Inc Borsa (IONS) Ultime notizie

04:04 AM

Transthyretin Amyloidosis Treatment Market Top PlayersIonis - openPR

04:04 AM

Nov 20, 2024

Ionis Announces Pivotal Phase 3 Trial Design for ION582 in Angel - GuruFocus.com

Nov 20, 2024

Multiple System Atrophy Market Growth to Accelerate in Forecast Period (2024-2034), DelveInsight Analyzes | Ionis Pharma, Biohaven Pharma, Lundbeck A/S, Alterity Therapeutics, Theravance Biopharma - The Globe and Mail

Nov 20, 2024

Ionis reaches agreement on phase 3 trial design for Angelman candidate - MSN

Nov 20, 2024

10 Best Genomics Stocks To Buy Right Now - Insider Monkey

Nov 20, 2024

Nov 19, 2024